The good news is you dont have to pull never-ending dollars from your coffers to give care at the right time to your people
The FDA based its decision on results from the Researching Cardiovascular Events with a Weekly Incretin in Diabetes (REWIND) trial
Data were pooled using random-effects models, and subgroup analyses were performed by drug type and treatment duration
Comparing Semaglutide, Tirzepatide, and Dual-Compound Options Semaglutide targets GLP-1 receptors alone and produced average weight loss of 15% in landmark trials, making it highly effective for most patients
In non-obese diabetic (NOD) mice which are a murine model of T1DM, GLP-1RAs can improve immune functions and inflammatory responses as well as mitigating against islet cell damage, an action which may be related to the decrease in the expression of miR-19b [145]
Trapp S, Brierley DI (2022) Brain GLP-1 and the regulation of food intake: GLP-1 action in the brain and its implications for GLP-1 receptor agonists in obesity treatment